<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836897</url>
  </required_header>
  <id_info>
    <org_study_id>A-valve-2020-07</org_study_id>
    <nct_id>NCT04836897</nct_id>
  </id_info>
  <brief_title>PrizValve® Transcatheter Aortic Valve Replacement Study</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of the Transcatheter Aortic Valve Replacement System in Patients With Severe Aortic Valve Stenosis Disease at High Surgical Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai NewMed Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai NewMed Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the effectiveness and safety of the&#xD;
      transcatheter aortic valve system in the treatment of patients with severe aortic stenosis&#xD;
      who are at high risk of surgery or who are not suitable for surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an multicenter, single-arm, prospective, safety and performance clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause mortality within 12 months of TAVI procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>2-5 years</time_frame>
    <description>All-cause mortality within 2-5 years of TAVI procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>immediate post-surgical</time_frame>
    <description>Device success after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>immediate post-surgical</time_frame>
    <description>Procedural success after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Myocardial infarction</measure>
    <time_frame>30 days、6 months、1-5 years</time_frame>
    <description>Rate of Myocardial infarction after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All disabling stroke</measure>
    <time_frame>30 days、6 months、1-5 years</time_frame>
    <description>Rate of All disabling stroke after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe bleeding</measure>
    <time_frame>30 days、6 months、1-5 years</time_frame>
    <description>Rate of Severe bleeding after TAVI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PrizValve® valve and transapical delivery system</intervention_name>
    <description>Transcatheter aortic valve replacement system</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 70 years ;&#xD;
&#xD;
          2. Patients with symptomatic severe aortic valve stenosis (evaluated by echocardiography:&#xD;
             transaortic valve pressure gradient ≥40mmHg (1mmHg=0.133kPa), or transaortic valve&#xD;
             blood flow rate ≥4m/s, or aortic Valve area&lt;1.0cm2, or AVA &lt;0.5cm2 /m2);&#xD;
&#xD;
          3. NYHA ≥ II;&#xD;
&#xD;
          4. Life expectancy&gt; 12 months;&#xD;
&#xD;
          5. Patients who are anatomically suitable for transcatheter aortic valve implantation;&#xD;
&#xD;
          6. After evaluation by two or more cardiovascular surgeons, patients who are unsuitable&#xD;
             for surgery; or patients who refuse surgery after sufficient communication by the&#xD;
             surgeons and are at high risk of routine surgery;&#xD;
&#xD;
          7. Patients who can understand the purpose of the trial, voluntarily participate in and&#xD;
             signed informed consent form, and are willing to accept relevant examinations and&#xD;
             clinical follow-ups.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute myocardial infarction occurred within 1 month before this treatment;&#xD;
&#xD;
          2. Congenital single leaf aortic valve;&#xD;
&#xD;
          3. Any therapeutic cardiac operation (including placement of coronary drug-eluting&#xD;
             stents) within 30 days;&#xD;
&#xD;
          4. The patient's heart has been implanted with other artificial heart valves, artificial&#xD;
             rings, or severe mitral regurgitation (&gt;3+);&#xD;
&#xD;
          5. Blood system diseases or abnormalities, including leukopenia (WBC&lt;3×109/L), acute&#xD;
             anemia (HB &lt;90g/L), thrombocytopenia (PLT&lt;50×109/L), bleeding constitution and&#xD;
             coagulopathy ；&#xD;
&#xD;
          6. Untreated severe coronary artery stenosis that requires revascularization;&#xD;
&#xD;
          7. Patients with hemodynamic or respiratory instability, requiring continuous mechanical&#xD;
             heart assistance or mechanical ventilation;&#xD;
&#xD;
          8. Patients who need emergency surgery for any reason;&#xD;
&#xD;
          9. Hypertrophic cardiomyopathy with obstruction;&#xD;
&#xD;
         10. Severe left ventricular dysfunction, left ventricular ejection fraction (LVEF) &lt;20%;&#xD;
&#xD;
         11. The echocardiogram indicates the presence of a heart mass, thrombus or vegetation;&#xD;
&#xD;
         12. A history of acute peptic ulcer or upper gastrointestinal bleeding within 3 months;&#xD;
&#xD;
         13. Are allergic to cobalt-chromium alloys or contrast agents, and cannot tolerate&#xD;
             anticoagulation and antiplatelet therapy;&#xD;
&#xD;
         14. The diameter of the aortic valve annulus &lt;16mm or &gt;28mm;&#xD;
&#xD;
         15. In any case, patients who refuse surgical treatment in emergency situations;&#xD;
&#xD;
         16. Cerebrovascular accident occurred within 3 months, not including transient ischemic&#xD;
             attack;&#xD;
&#xD;
         17. Renal insufficiency is decompensated (creatinine&gt;177umol/L), and/or end-stage renal&#xD;
             disease requires long-term dialysis;&#xD;
&#xD;
         18. Severe aortic diseases, including abdominal aortic or thoracic aortic aneurysm,&#xD;
             obvious curvature of the aortic arch, atherosclerosis of the aortic arch, narrowing of&#xD;
             the abdominal or thoracic aorta, and obvious curvature or extension of the thoracic&#xD;
             aorta;&#xD;
&#xD;
         19. The iliac-femoral artery is severely obstructed with calcification, severely tortuous&#xD;
             or unable to place the 1418F catheter sheath kit;&#xD;
&#xD;
         20. Active infective endocarditis or other active infections;&#xD;
&#xD;
         21. Aortic valve leaflets calcified plaque close to the coronary ostium;&#xD;
&#xD;
         22. Severe disability Alzheimer's disease and unable to take care of oneself in life;&#xD;
&#xD;
         23. Those who have participated in clinical trials of other drugs or medical devices&#xD;
             before entering the group and have not yet reached the time limit of the primary&#xD;
             research endpoint;&#xD;
&#xD;
         24. The researcher judged that the patient had poor compliance and could not complete the&#xD;
             study as required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen mao, Chief</last_name>
    <role>Study Chair</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang chunyang, CRA</last_name>
    <phone>(86)-21-20788668</phone>
    <email>cywang@newmed.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xie xuyang</last_name>
    <phone>(86)-21-20788668</phone>
    <email>xyxie@newmed.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, West China Hospital, Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen mao, Chief</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

